DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae.
about
Crystal structures of Escherichia coli topoisomerase IV ParE subunit (24 and 43 kilodaltons): a single residue dictates differences in novobiocin potency against topoisomerase IV and DNA gyraseBreakage-reunion domain of Streptococcus pneumoniae topoisomerase IV: crystal structure of a gram-positive quinolone targetExploring the active site of the Streptococcus pneumoniae topoisomerase IV-DNA cleavage complex with novel 7,8-bridged fluoroquinolonesFluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance.Resistance to multiple fluoroquinolones in a clinical isolate of Streptococcus pyogenes: identification of gyrA and parC and specification of point mutations associated with resistanceCharacterization of the quinolone resistant determining regions in clinical isolates of pneumococci collected in CanadaRisk factors associated with colonization by pneumococci with reduced susceptibility to fluoroquinolones in adult outpatients.Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin.Biological cost of single and multiple norfloxacin resistance mutations in Escherichia coli implicated in urinary tract infections.Molecular detection of antimicrobial resistanceSparfloxacin selects gyrase mutations in first-step Mycoplasma hominis mutants, whereas ofloxacin selects topoisomerase IV mutations.Activity of gemifloxacin against penicillin- and ciprofloxacin-resistant Streptococcus pneumoniae displaying topoisomerase- and efflux-mediated resistance mechanisms.Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory seSelective targeting of topoisomerase IV and DNA gyrase in Staphylococcus aureus: different patterns of quinolone-induced inhibition of DNA synthesisFluoroquinolone resistance associated with target mutations and active efflux in oropharyngeal colonizing isolates of viridans group streptococci.Analysis of ciprofloxacin activity against Streptococcus pneumoniae after 10 years of use in the United States.Benchmarking the in vitro activities of moxifloxacin and comparator agents against recent respiratory isolates from 377 medical centers throughout the United States.Cloning and nucleotide sequence of the DNA gyrase (gyrA) gene from Mycoplasma hominis and characterization of quinolone-resistant mutants selected in vitro with trovafloxacin.Mechanisms and frequency of resistance to premafloxacin in Staphylococcus aureus: novel mutations suggest novel drug-target interactionsMutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus.Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniaeTarget preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition.parC mutations in fluoroquinolone-resistant Borrelia burgdorferi.DNA gyrase and topoisomerase IV mutations associated with fluoroquinolone resistance in Proteus mirabilis.Role of the water-metal ion bridge in mediating interactions between quinolones and Escherichia coli topoisomerase IV.Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone.DX-619, a novel des-fluoro(6) quinolone manifesting low frequency of selection of resistant Staphylococcus aureus mutants: quinolone resistance beyond modification of type II topoisomerases.Role of the extended alpha4 domain of Staphylococcus aureus gyrase A protein in determining low sensitivity to quinolones.Bacillus anthracis GrlAV96A topoisomerase IV, a quinolone resistance mutation that does not affect the water-metal ion bridgegyrA mutations in ciprofloxacin-resistant Bartonella bacilliformis strains obtained in vitroContribution of the 8-methoxy group to the activity of gatifloxacin against type II topoisomerases of Streptococcus pneumoniae.Topoisomerase targeting with and resistance to gemifloxacin in Staphylococcus aureusFirst characterization of fluoroquinolone resistance in Streptococcus suis.Drug interactions with Bacillus anthracis topoisomerase IV: biochemical basis for quinolone action and resistance.Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections.In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone.Mechanisms of drug resistance: quinolone resistance.ATP-bound conformation of topoisomerase IV: a possible target for quinolones in Streptococcus pneumoniaeActivities of different fluoroquinolones against Bacillus anthracis mutants selected in vitro and harboring topoisomerase mutations.
P2860
Q24567584-BFFF3506-1085-4920-9F3C-8BA21437A29CQ27303056-6271F5F8-6B13-4993-97D7-A4BF6806638AQ28828291-20EF5008-39AA-4D55-8F0C-C39E6D9C965CQ33594174-E7849CB6-D270-4EB3-B806-F09441163274Q33595145-5D759486-5F81-4408-86A4-97E25E460991Q33663032-42149034-D81D-4948-B2CF-458E10659A3EQ33752905-266CF732-8466-41B5-8D01-A779F3550EF6Q33770013-0BE2BF67-04D7-4016-927F-FB5A584200F1Q33836664-7FE8D921-3F49-4C30-B415-9A7481385543Q33975793-9A4028C0-5664-4154-AA86-5E41D495D3D9Q33977877-DC9386ED-F96F-4DB2-A1E8-79159BE0B4D1Q33978324-6BBCF756-9101-4B4D-AE65-29EB6022BC95Q33978849-240D1E18-5284-4044-BA32-CE198C422E68Q33980255-07C176DF-0A51-4281-B2F6-19FA8924CA32Q33980313-40DE18A0-1213-4A2A-9989-015812DE51AAQ33980574-DC3B9120-F586-4BD9-8C0A-22E120DBFF54Q33980689-30597732-0575-406F-BEBF-41CB9C8B3960Q33980747-2E573239-B82E-4D47-8B32-E0CB86345EF4Q33980991-532BFAC5-5CF0-43DC-BAEB-5F77271BEA7DQ33981343-ECF89EC8-56F0-40C8-933D-576A816D6E34Q33983092-429179BE-3E82-45A0-B99F-9634FB7571DEQ33983643-2972FE88-26C8-4B70-9E43-AE600A7A276DQ33983660-5B6ED78F-8E48-410A-9A88-658EC283194FQ34077147-E639D8E7-A032-4744-9E5D-FF8D836E08A9Q34111196-BFD842F0-A4F9-4B67-87E7-8B3D808C3197Q34119765-003E29D4-3CCF-4AEE-B12B-D93240FC0985Q34142238-C819864A-DDA4-491C-8198-772784F15738Q34228402-A97B066B-BE7B-456B-8F29-AA2868670499Q34352135-0080193D-40A7-4FD5-9369-7151D5D2E8DDQ34597404-42DA1814-2981-4317-A8AC-BCBA374C20C3Q34720856-EF74A349-FB5F-4F45-9A49-F21708B6FA13Q34721556-E1FD807A-2515-44D4-A2E1-677DA4A223A2Q34725095-691CA1A9-DD02-4E15-A42F-2B9687020AD4Q35636018-E2A24D7E-DF19-4AB7-8910-9461DA5983F4Q35682250-1CB85803-E667-4B66-9A06-A3FB0BA29BD0Q36048167-724AB43F-F111-4CC5-8555-F0909026363DQ36048301-59BCC488-D468-4F78-BB46-335125AC8E6FQ36225422-609448C2-E7E9-4D0D-BFE7-71C4E5DD0C37Q36474350-435AB003-C8D1-44D3-B725-77B8D513EE38Q36669771-847A93C6-758F-41F3-B397-0BC64B6FC2D9
P2860
DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
DNA gyrase and topoisomerase I ...... n in Streptococcus pneumoniae.
@en
DNA gyrase and topoisomerase I ...... n in Streptococcus pneumoniae.
@nl
type
label
DNA gyrase and topoisomerase I ...... n in Streptococcus pneumoniae.
@en
DNA gyrase and topoisomerase I ...... n in Streptococcus pneumoniae.
@nl
prefLabel
DNA gyrase and topoisomerase I ...... n in Streptococcus pneumoniae.
@en
DNA gyrase and topoisomerase I ...... n in Streptococcus pneumoniae.
@nl
P2860
P356
P1476
DNA gyrase and topoisomerase I ...... on in Streptococcus pneumoniae
@en
P2093
P2860
P304
P356
10.1128/AAC.42.11.2810
P407
P577
1998-11-01T00:00:00Z